Evaluation of a five-gene signature associated with stromal infiltration for diffuse large B-cell lymphoma

被引:0
作者
Ying-Yu Nan [1 ]
Wen-Jun Zhang [1 ]
De-Hong Huang [1 ]
Qi-Ying Li [1 ]
Yang Shi [1 ]
Tao Yang [1 ]
Xi-Ping Liang [1 ]
Chun-Yan Xiao [1 ]
Bing-Ling Guo [1 ]
Ying Xiang [1 ]
机构
[1] Department of Hematology, Chongqing University Cancer Hospital
关键词
Diffuse large B-cell lymphoma; Co-expression; Overexpression; Stromal score; Cancer-associated fibroblasts; Therapeutic target;
D O I
暂无
中图分类号
R733.1 [网状内皮系统肿瘤];
学科分类号
100214 ;
摘要
BACKGROUND Diffuse large B-cell lymphoma(DLBCL) is a common non-Hodgkin lymphoma. The development of immunotherapy greatly improves the patient prognosis but there are some exceptions. Thus, screening for better biomarkers for prognostic evaluation could contribute to the treatment of DLBCL patients.AIM To screen the novel mediators involved in the development of DLBCL.METHODS The GSE60 dataset was applied to identify the differentially expressed genes(DEGs) in DLBCL, and the principal components analysis plot was used to determine the quality of the included samples. The protein-protein interactions were analyzed by the STRING tool. The key hub genes were entered into to the GEPIA database to determine their expressions in DLBCL. Furthermore, these hub gene alterations were analyzed in cBioportal. The UALCAN portal was employed to analyze the expression of the hub genes in different stages of DLBCL. The Estimation of Stromal and Immune cells in Malignant Tumor tissues using Expression data Score was conducted to evaluate the correlation between the gene expression and tumor purity. The gene-gene correlation analysis was conducted in the GEPIA. The stromal score analysis was conducted in TIMER to confirm the correlation between the gene expression and infiltrated stromal cells. The correlation between the indicated genes and infiltration level of cancerassociated fibroblasts(CAFs) was also completed in TIMER with two methods, MCP-Counter and Tumor immune dysfunction and exclusion. The correlation between fibronectin(FN1) protein level and secreted protein acidic and cysteinerich(SPARC) messenger ribonucleic acid expression was confirmed in the c Bioportal.RESULTS The top 20 DEGs in DLBCL were identified, and the principal components analysis plot confirmed the quality of the significant DEGs. The pairwise correlation coefficient analysis among all samples showed that these DEGs have a certain co-expression pattern. The DEGs were subjected to STRING to identify the hub genes, alpha-2-macroglobulin(A2 M), cathepsin B(CTSB), FN1, matrix metallopeptidase 9(MMP9), and SPARC. The five hub genes were confirmed to be overexpressed in DLBCL. The c Bioportal portal detected these five hub genes that had gene alteration, including messenger ribonucleic acid high amplification and missense mutation, and the gene alteration percentages of A2 M, FN1, CTSB, MMP9, and SPARC were 5%, 8%, 5%, 2.7%, and 5%, respectively. Furthermore, the five hub genes had a potential positive correlation with tumor stage. The correlation analysis between the five genes and tumor purity confirmed that the five genes were overexpressed in DLBCL and had a positive correlation with the development of DLBCL. More interestingly, the five genes had a significant correlation with the stromal infiltration scores. The correlation analysis between the fives genes and CAFs also showed a significant value, among which the top two genes, FN1 and SPARC, had a remarkable co-expression pattern.CONCLUSION The top DEGs were identified, and the five hub genes were overexpressed in DLBCL. Furthermore, the gene alterations were confirmed and the positive correlation with tumor purity revealed the overexpression of the five genes and close association with the development of DLBCL. More interestingly, the five genes were positively correlated with stromal infiltration, especially in CAFs. The top two genes, FN1 and SPARC, showed a co-expression pattern, which indicates their potential as novel therapeutic targets for DLBCL.
引用
收藏
页码:4585 / 4598
页数:14
相关论文
共 19 条
[1]   Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma [J].
Meriranta, Leo ;
Pasanen, Annika ;
Alkodsi, Amjad ;
Haukka, Jari ;
Karjalainen-Lindsberg, Marja-Liisa ;
Leppa, Sirpa .
BLOOD ADVANCES, 2020, 4 (15) :3742-3753
[2]   Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy [J].
Smith, Stephen D. ;
Till, Brian G. ;
Shadman, Mazyar S. ;
Lynch, Ryan C. ;
Cowan, Andrew J. ;
Wu, Qian W. ;
Voutsinas, Jenna ;
Rasmussen, Heather A. ;
Blue, Katherine ;
Ujjani, Chaitra S. ;
Shustov, Andrei ;
Cassaday, Ryan D. ;
Fromm, Jonathan R. ;
Gopal, Ajay K. .
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (06) :1119-1126
[3]   Identification of potential key genes in gastric cancer using bioinformatics analysis [J].
Wang, Wei ;
He, Ying ;
Zhao, Qi ;
Zhao, Xiaodong ;
Li, Zhihong .
BIOMEDICAL REPORTS, 2020, 12 (04) :178-192
[4]   Prognostic impact of abdominal lymph node involvement in diffuse large B-cell lymphoma [J].
Abdulla, Maysaa ;
Guglielmo, Priscilla ;
Hollander, Peter ;
Astrom, Gunnar ;
Ahlstrom, Hakan ;
Enblad, Gunilla ;
Amini, Rose-Marie .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (03) :207-213
[5]  
Follicular lymphoma: 2020 update on diagnosis and management[J] . Freedman Arnold,Jacobsen Eric.American journal of hematology . 2020 (3)
[6]   Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma [J].
Karkhanis, Vrajesh ;
Alinari, Lapo ;
Ozer, Hatice Gulcin ;
Chung, Jihyun ;
Zhang, Xiaoli ;
Sif, Said ;
Baiocchi, Robert A. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2020, 295 (05) :1165-1180
[7]   Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306) [J].
Pettengell, Ruth ;
Dlugosz-Danecka, Monika ;
Andorsky, David ;
Belada, David ;
Georgiev, Pencho ;
Quick, Donald ;
Singer, Jack W. ;
Singh, Simran B. ;
Pallis, Athanasios ;
Egorov, Anton ;
Salles, Gilles .
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (02) :240-248
[8]  
A Four Gene-Based Risk Score System Associated with Chemoradiotherapy Response and Tumor Recurrence in Rectal Cancer by Co-Expression Network Analysis[J] . Sun Yanwu,Zhang Yiyi,Wu Xuejing,Chi Pan.OncoTargets and therapy . 2020 (defa)
[9]   Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma [J].
Harker-Murray, Paul D. ;
Pommert, Lauren ;
Barth, Matthew J. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (08) :1125-1134
[10]   The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-cell Lymphoma in the Era of CAR-T Cell Therapy [J].
Lekakis, Lazaros J. ;
Moskowitz, Craig H. .
HEMASPHERE, 2019, 3 (06)